Lindbrook Capital’s AbCellera Biologics ABCL Stock Holding History

Lindbrook Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$2.25K	Sell	1,011 -7,396	-88%	-$21.2K	﹤0.01%	2243
2024 Q4	$24.6K	Buy	8,407 +3,015	+56%	+$8.4K	﹤0.01%	1159
2024 Q3	$14K	Buy	5,392 +2,904	+117%	+$8.05K	﹤0.01%	1497
2024 Q2	$7.36K	Buy	2,488 +1,429	+135%	+$5.41K	﹤0.01%	1803
2024 Q1	$4.8K	Sell	1,059 -472	-31%	-$2.41K	﹤0.01%	1909
2023 Q4	$8.74K	Buy	1,531 +695	+83%	+$3.22K	﹤0.01%	1615
2023 Q3	$3.85K	Buy	836 +779	+1,367%	+$4.74K	﹤0.01%	1884
2023 Q2	$368	Buy	57 +24	+73%	+$164	﹤0.01%	2564
2023 Q1	$249	Buy	+33	New	+$300	﹤0.01%	2700

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Lindbrook Capital's ABCL Position: Q1 2025 in Review

Lindbrook Capital reduced its AbCellera Biologics (ABCL) stake by 88% in Q1 2025, selling an estimated $21.2K and leaving 1,011 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

Lindbrook Capital first reported a position in ABCL in Q1 2023 and has held it in 9 quarters since. The position peaked at $24.6K in Q4 2024. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

Lindbrook Capital held 1,011 shares of AbCellera Biologics worth $2.25K as of Q1 2025.
Lindbrook Capital sold 7,396 AbCellera Biologics shares in Q1 2025, an estimated $21.2K.
AbCellera Biologics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2243 holding.
Lindbrook Capital first reported a position in AbCellera Biologics in Q1 2023 and has held it in 9 quarters since.
Lindbrook Capital's AbCellera Biologics position peaked at $24.6K in Q4 2024.
129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.